InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Hugh Rogers, CEO of XPhyto Therapeutics Corp.

Rhea-AI Summary

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) has launched a 25-minute COVID-19 RT-PCR test, gaining CE-IVD approval and focusing on commercialization in Germany and Austria. CEO Hugh Rogers highlighted the company’s ability to rapidly take products from conception to market within ten months. XPhyto is also expanding its drug formulation program through the acquisition of Vektor Pharma TF, planning multiple pilot studies including one for a Parkinson's treatment. Rogers emphasized a strong operational strategy and a robust product pipeline.

Positive

• Launch of a 25-minute COVID-19 RT-PCR test with European approval.
• Focus on commercialization in Germany and strategic expansion into Austria and Israel.
• Acquisition of Vektor Pharma enhances drug formulation capabilities.
• Experienced leadership with new hire Manfred Buchberger driving product launch.

Negative

• None.

NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of an exclusive The Bell2Bell Podcast interview with Hugh Rogers, CEO and Director of life sciences technology accelerator XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT).

During the interview with IBN’s Communications Director Jonathan Keim, Rogers offered an operational update, discussing the company’s most recent achievements and future plans. XPhyto Therapeutics recently obtained European approval and launched an effective 25-minute PCR (polymerase chain reaction) test for COVID-19, with an initial focus on the German market and several other initiatives underway.

“This is an exciting time for the company. We’ve taken this product from invention to prototype to validation to commercial approval in about ten months,” Rogers said. He explained that the company’s 25-minute COVID-19 RT-PCR test (Covid-ID Lab) sits between a rapid antigen test and a centralized automated high-throughput PCR, offering diagnostic quality, fast results and ease of administration at point of care, whether that is a medical clinic, a pharmacy, a cruise ship turnover or airport, or any mobile testing center.

Following the CE-IVD approval (European certification) of the test, the company is focused on commercialization in Germany, with a footprint in Austria, while also conducting a number of other initiatives. One such initiative is in Israel, where XPhyto is looking to obtain approval for its Covid-ID Lab, as that market could also serve as a launching point to a number of Middle Eastern countries. “There is certainly no shortage of opportunities, particularly close to Europe,” Rogers added.

XPhyto’s CEO then discussed the recent addition of Manfred Buchberger as Head of Corporate Development at wholly owned German subsidiary XP Diagnostics GmbH. Buchberger was formerly global head of sales and CEO of a major European diagnostics and analytics company, which he helped grow from a couple of million dollars a year to nearly $1 billion in revenue. “He is an expert in his field, and we’re very fortunate to have him on board,” Rogers explained. “He is leading our product launch and sales initiatives and we’re just very happy to have him involved and looking to expand his role in the near future.”

When asked to comment on how XPhyto became a $150-million-dollar company listed on three different exchanges, Rogers underlined that his organization has evolved significantly and is now something of a technology accelerator/incubator making early-stage investments and always looking for low-cost or value-driven investment opportunities, with scalability platform technologies and largely driven by its scientific network. That means easier access to opportunities before anyone else, as well as securing further opportunities by virtue of the company’s success so far, he said.

“I think we’ve demonstrated now that we can take a product to market in a very short period of time, we have a pipeline of diagnostics products, we have a drug formulation business, as well as a psychotropic or psychedelic medicines program,” Rogers explained. “So, a lot of exciting opportunities, certainly timely, and the fact that we can move very quickly and allocate capital very effectively and quickly is helping our growth plans.”

Detailing its drug formulation program, Rogers discussed the acquisition of Vektor Pharma TF, a thin film drug formulator based in Germany. “They have about 20+ scientists working there, and their focus is both transdermal drug delivery systems and oral dissolvables; for example, sublingual dissolvable strips, buccal dissolvable formulas,” he said.

Rogers added that XPhyto and Vektor have four pilot studies planned for this year and have already completed a first one in Q1 successfully for their lead product, a Parkinson’s transdermal drug delivery system for Rotigotine. He explained that this is a generic product, and that they have a number of hybrid generic products in the pipeline as well.

“This goes back to our investment strategy – Vektor really has scalable opportunities, so for relatively low costs in the generic or hybrid generic space, we can develop a drug formula using existing API, possibly an existing drug platform such as transdermal, or maybe a hybrid situation where we’ve reformulated in a new delivery system,” Rogers added. “But, in any case, it’s low cost to market, we don’t have to establish safety or efficacy of this particular compound or focus on the drug formulation side.”

The XPhyto CEO concluded the interview reiterating that this was an exciting time for the company, with multiple opportunities ahead, and underlined that he was looking forward to making more announcements on that front later this year.

Join InvestorBrandNetwork’s Jonathan Keim and Hugh Rogers, CEO and director of XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), to learn more about XPhyto’s 25-minute COVID-19 RT-PCR test distribution plans, its expert management team and innovative drug formulation program.

To hear the whole interview and subscribe for future episodes, visit: https://podcast.bell2bell.com

The latest installment of The Bell2Bell Podcast continues to reinforce InvestorBrandNetwork’s commitment to the expansion of its robust network of brands, client partners, followers and the growing IBN Podcast Series. For more than 15 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About InvestorBrandNetwork
The InvestorBrandNetwork (“IBN”) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.
For more information on IBN, visit https://www.InvestorBrandNetwork.com.

Please see full terms of use and disclaimers on the InvestorBrandNetwork website, applicable to all content provided by IBN wherever published or re-published: https://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

FAQ

What recent product did XPhyto Therapeutics launch for COVID-19?

XPhyto Therapeutics launched a 25-minute COVID-19 RT-PCR test, which has received CE-IVD approval.

What markets is XPhyto targeting with its COVID-19 test?

XPhyto is focusing on the German market and plans expansion into Austria and Israel.

Who is leading XPhyto's product launch initiatives?

Manfred Buchberger is the new Head of Corporate Development leading the product launch initiatives at XPhyto.

What is the significance of XPhyto's drug formulation program?

XPhyto's drug formulation program includes the acquisition of Vektor Pharma, enhancing its capabilities in developing transdermal and oral drug delivery systems.

How quickly does XPhyto take products to market?

XPhyto reported being able to take products from invention to market in about ten months.